{"name":"Stoke Therapeutics","slug":"stoke","ticker":"STOK","exchange":"NASDAQ","domain":"stoketherapeutics.com","description":"Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based me","hq":"Bedford, MA","founded":0,"employees":"170","ceo":"Ed Kaye, M.D.","sector":"Genetic Medicine / Neurology","stockPrice":35.82,"stockChange":2.04,"stockChangePercent":6.04,"marketCap":"$2.1B","metrics":{"revenue":184420000,"revenueGrowth":-93.8,"grossMargin":100,"rdSpend":137922000,"netIncome":-6885000,"cash":284670016,"dividendYield":0,"peRatio":-11.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"STK-001 - Single Ascending Doses","genericName":"STK-001 - Single Ascending Doses","slug":"stk-001-single-ascending-doses","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"STK-001 - Single Ascending Doses","genericName":"STK-001 - Single Ascending Doses","slug":"stk-001-single-ascending-doses","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Stoke Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for STK-002","summary":"Stoke Therapeutics announced that the FDA has cleared the IND application for STK-002, a proprietary therapy for the treatment of Angelman syndrome.","drugName":"STK-002","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Stoke Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Stoke Therapeutics reported its third quarter 2023 financial results, with a net loss of $23.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Stoke Therapeutics Announces Collaboration with the National Institutes of Health (NIH)","summary":"Stoke Therapeutics announced a collaboration with the NIH to develop new treatments for genetic disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"pipeline","source":"simplywall.st","summary":"Assessing Stoke Therapeutics (STOK) Valuation After Strong 1 Year Shareholder Returns - simplywall.st","headline":"Assessing Stoke Therapeutics (STOK) Valuation After Strong 1 Year Shareholder Returns","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-29","type":"pipeline","source":"simplywall.st","summary":"Stoke Therapeutics (STOK) Valuation After Strong 2025 Results And Progress In STK-002 And Zorevunersen - simplywall.st","headline":"Stoke Therapeutics (STOK) Valuation After Strong 2025 Results And Progress In STK-002 And Zorevunersen","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-04","type":"pipeline","source":"simplywall.st","summary":"Is Stoke Therapeutics (STOK) Still Attractive After A 346% One Year Share Price Surge - simplywall.st","headline":"Is Stoke Therapeutics (STOK) Still Attractive After A 346% One Year Share Price Surge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOV1dqM3QxTllNekk5MWVfMktsM2NFZHlXV0plOHdWdWhDX19mTmttQ2JpWTRFb2pxMWR2OHlKQTNYTlp1cUh2b294bXlGX3dFOFZtd09ScFVhejNWMVE3dUdxb2IwZVFNNWNHeHpaZWdRMU9qMlVVSEM0eEpoWFVvenJyTnRsQm9DRlZGVTE2YjRaT0NsT2p2dzRMZE1oOVAwNmlUOW9CU1o2NDRybF9hRVdkb3JEMzhSR05ZLVdvNWtkRWdLcmRmMWNpUk1fUjh4bXhfTUNMNA?oc=5","date":"2026-02-12","type":"pipeline","source":"The Globe and Mail","summary":"Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail","headline":"Wall Street Analysts Are Bullish on Top Healthcare Picks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNdW5wTF9Jd3JoelhYLXFzYzZqWTBJdmdrZ0l0MlVjXzRsc1dWZXBtdUJrUkhWV3JjVU90Z3huYTlzeldYYUNpVXB6YlUybW9ONGtEUnk0cnVLMkYydzl0X2R2STlQMmNPLUtFMWdWNm9nZnllbDh2eU1tdzk4WFRBNU1vSVB5Z3hlYzktZVF5dlVhNk9KV21yeEJIUkhNQUJBWjlSRzY4SmJPV2Vk?oc=5","date":"2026-01-12","type":"trial","source":"Endpoints News","summary":"Eisai licenses Nuvation lung cancer pill; Alnylam’s stock dips after sales data report - Endpoints News","headline":"Eisai licenses Nuvation lung cancer pill; Alnylam’s stock dips after sales data report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxORzFBcjNqNGk5Q2ZiZDl4RFhmZXJmRW55aGtlODRLN1J1bkZkWmxteVpMbS1zbWl5WjZjT2dGTlcyR3hCRUNlSnBDVWR4N1BiM0QxS0tCRG5nbHJjZ1ItakF2dXZFcDFfZmpsOXA0M0tXalhsT1ZTXzlNVWJ6eTlIWHBPSUpLZ0dHMEZIQ29Wd0NtTm5QRjFrOWFqRGkweXE3RW5ndW93TV9pRHlUd01zbGtUWFNvZHNIdzRNOU5WWmo1Zw?oc=5","date":"2025-10-06","type":"pipeline","source":"Business Wire","summary":"Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer - Business Wire","headline":"Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQUzNGYmNuNVF0S29uaDRoVEt3dmhpVTZBSUU2LUE2MzVEZ1hYSEhYY2xjMmpnaldkR1VsOGM2U0Nta1Z0MnUxc2tNS0xVNERBNjM0Qm00bXBfX3NJcTBqQU1rUENMNFJBMm5kMzhaZFg0Q01wNDdpNGM1Qm9lYlE1cA?oc=5","date":"2025-10-06","type":"pipeline","source":"The Business Journals","summary":"Former Vertex COO named chief executive at Dravet-focused biotech - The Business Journals","headline":"Former Vertex COO named chief executive at Dravet-focused biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQd0o3TnhUMGZkeEI3YlJyaHlpN0xzOExtLXVlYUs4NUFNT2JsTmMwVkJfc2t4NE1aWkVEQkFiS3FieFFVUlVJTUhCcXZGR3pVNzg3d2UwSFZlS09yZ3VXRjB2b05kQ1E2azV6cjh2a1d6c0VGY1pVdGVubjhrUkhqamQxN18ybnY2cXlHNXBMMFU?oc=5","date":"2025-08-27","type":"earnings","source":"Seeking Alpha","summary":"Stoke Therapeutics: Vulnerable To Profit Taking (NASDAQ:STOK) - Seeking Alpha","headline":"Stoke Therapeutics: Vulnerable To Profit Taking (NASDAQ:STOK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPSFNzd2lxZzktOERtU2RYZ0dRNEdMQnhoNzVZR01UeDVYWGk5SWlaV0x2STlzcEdGUmE2Zk5MOWFzS1JfMGRSS0RIM2FxUUowemJJbEFPdFVocjFuVG9hdFRrNEpPZTZqZjhXeWZlYXpaVXp0SUFlRXBUdVVpWUVybm05eWtueHJYemxOT2czWk9iY3UzcUsxSkxpLW53a3ItdDFUQkZteTFXLUJuWFY4czNhUzQ2ZmhvQXhGV1RzM0VlSnB5Vkpz?oc=5","date":"2025-08-11","type":"trial","source":"Biogen","summary":"Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Biogen","headline":"Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1GQnIxcFRkak9nWm9nNklSWUw4MFhzUDRHM1J3aDZCX2hpeHV5RFY4VVVnZWpQaE16TGY1Q0J6SjloWVZxOV9IXzZVS1MzU0FEN2M3TnFoUmJaSXZCQms3c0lfTVpac0hw?oc=5","date":"2025-07-10","type":"regulatory","source":"MarketBeat","summary":"Stoke Therapeutics (STOK) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $STOK - MarketBeat","headline":"Stoke Therapeutics (STOK) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $STOK","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPaHNoZTNfemY5TjNtRW53SDlRS2JncW1fWm5mSW54Ujl6NWNfdTZQUzk5cDhtQ0VjRVZRTHN1cEtzTGN1OE5RLWJoV0ZJeGFNNV8zUXRyWWQyd1lkWDNyZkVWdzRVcHF0bG1qckpkZmZldlRqejhwX1FQdExaVU1MaQ?oc=5","date":"2025-03-19","type":"pipeline","source":"The Pharma Letter","summary":"Stoke Therapeutics announces CEO transition - The Pharma Letter","headline":"Stoke Therapeutics announces CEO transition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNVUxBUmhVNXg4eEJUeXFYeW0yMjNDSWxRSktnMzRjTldpbHVWYm1Oa3pFZUthbmtzWi1mZDFaY1dzWXhFQ3RQZkc2TWNTLTMxd1hEZmQ5MlBNWHl2ZzhINHdIanE1c2RxZi0yTEdxd2NRUUJjSms3bDF2WXpTUllPN3p5T3MwOWZKcGpFdkZ3MEpCUTdyeHRQUG9lYk1wWFVmTnJBYWNNTTNOVUE5MXZnYVNNc21lVXFBM2dqeTB4SDdEeUU?oc=5","date":"2025-02-18","type":"deal","source":"Biogen","summary":"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and N","headline":"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dr","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Ionis Pharmaceuticals","Biogen","Pfizer"],"therapeuticFocus":["Genetic Medicine","Neurology"],"financials":{"source":"sec_edgar","revenue":184420000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":184420000,"period":"2025-12-31"},{"value":36555000,"period":"2024-12-31"},{"value":36555000,"period":"2024-12-31"},{"value":8780000,"period":"2023-12-31"},{"value":8780000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":137922000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-6885000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":418434000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":35.82,"previousClose":33.78,"fiftyTwoWeekHigh":40.22,"fiftyTwoWeekLow":5.35,"fiftyTwoWeekRange":"5.35 - 40.22","fiftyDayAverage":33.21,"twoHundredDayAverage":26.06,"beta":1.22,"enterpriseValue":1717591680,"forwardPE":-11.3,"priceToBook":5.99,"priceToSales":11.49,"enterpriseToRevenue":9.31,"enterpriseToEbitda":-91.26,"pegRatio":0,"ebitda":-18820000,"ebitdaMargin":-10.2,"freeCashflow":33024624,"operatingCashflow":45585000,"totalDebt":4148000,"debtToEquity":1.2,"currentRatio":5.28,"returnOnAssets":-3.7,"returnOnEquity":-2.4,"analystRating":"","recommendationKey":"none","numberOfAnalysts":10,"targetMeanPrice":45.1,"targetHighPrice":60,"targetLowPrice":35,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.1,"institutionHeldPercent":119.1,"sharesOutstanding":59150790,"floatShares":43831327,"sharesShort":13384494,"shortRatio":16.93,"shortPercentOfFloat":22.6,"epsTrailing":-0.12,"epsForward":-3.18,"revenuePerShare":3.11,"bookValue":5.98,"officers":[{"age":59,"name":"Mr. Ian F. Smith A.C.A., C.P.A.","title":"CEO & Director"},{"age":66,"name":"Dr. Adrian R. Krainer Ph.D.","title":"Co-Founder & Independent Director"},{"age":48,"name":"Mr. Thomas Edward  Leggett","title":"Chief Financial Officer"},{"age":76,"name":"Dr. Edward M. Kaye M.D., Ph.D.","title":"Advisor & Director"},{"age":64,"name":"Dr. Barry S. Ticho FACC, M.D., Ph.D.","title":"Chief Medical Officer"},{"age":53,"name":"Ms. Isabel  Aznarez Ph.D.","title":"Co-Founder, Head of Research & Senior VP"},{"age":null,"name":"Doug  Snow","title":"Director of Communications & Investor Relations"},{"age":35,"name":"Mr. Jonathan  Allan J.D.","title":"Corporate Secretary & General Counsel"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.stoketherapeutics.com","phone":"781 430 8200"}}